Heart failure & cardiomyopathiesSecondary analysis
Effect of vutrisiran on components of health status in transthyretin amyloidosis with cardiomyopathy: the HELIOS-B study
- Secondary analysis of the HELIOS-B randomised trial
- double-blind
- placebo-controlled
Authors' conclusion
In HELIOS-B, vutrisiran was associated with improvement in a wide range of individual KCCQ components, with the greatest benefits observed in physical limitations and quality-of-life domains.
Study context
- Population
- Patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM)486 completed KCCQ at baseline and 30 months
- Participants
- 654 patients
- Comparison
- Vutrisiran vs placebo
- Primary endpoint
- Mean score changes from baseline in each of 23 KCCQ components (0 worst to 100 best)
- Follow-up
- 30 months
Primary result
KCCQ components, change from baseline
Median
+3.8
As reported in the abstract
Further findings
| Outcome | shift in age-KCCQ-OSS relationship (years) (95% CI) |
|---|---|
| Age-equivalent benefit (KCCQ-OSS vs age) · 30 months · approximately; KCCQ-OSS inversely related to age | 11 (3–20) |
KCCQ components, patients not on tafamidis at baseline (subgroup)
- Similar or greater benefits with vutrisiran
Original publication
Effect of vutrisiran on components of health status in transthyretin amyloidosis with cardiomyopathy: the HELIOS-B study. Eur J Heart Fail. Published 29 March 2026. doi:10.1093/ejhf/xuag088
Summarised from the published abstract; every number is checked against it